Summit Trail Advisors LLC Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Trail Advisors LLC trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,038 shares of the biopharmaceutical company’s stock after selling 64 shares during the quarter. Summit Trail Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $912,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Meyer Handelman Co. lifted its position in shares of Regeneron Pharmaceuticals by 11.4% during the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after purchasing an additional 435 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after purchasing an additional 3,385 shares in the last quarter. LPL Financial LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.3% during the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after purchasing an additional 3,479 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Regeneron Pharmaceuticals by 32.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after purchasing an additional 1,221 shares in the last quarter. Finally, Monetary Management Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 4.8% during the third quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock worth $901,000 after purchasing an additional 50 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent analyst reports. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Finally, Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $981.71.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph J. Larosa sold 1,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $950.00, for a total transaction of $950,000.00. Following the sale, the executive vice president now directly owns 38,543 shares of the company’s stock, valued at $36,615,850. The disclosure for this sale can be found here. In the last three months, insiders sold 9,095 shares of company stock valued at $8,729,766. 8.83% of the stock is owned by insiders.

Regeneron Pharmaceuticals Price Performance

REGN traded up $1.64 on Monday, reaching $958.64. The company had a trading volume of 351,998 shares, compared to its average volume of 498,218. The company has a fifty day moving average of $943.75 and a 200-day moving average of $897.24. The company has a market capitalization of $105.22 billion, a P/E ratio of 28.32, a PEG ratio of 2.74 and a beta of 0.17. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the prior year, the company earned $10.96 EPS. Regeneron Pharmaceuticals’s revenue was up .6% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.